{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:03:27Z","timestamp":1793653407265,"version":"4.5.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Flares correspond to fluctuations in disease activity or symptoms. They should be avoided in chronic inflammatory diseases. In axial spondyloarthritis (axSpA), work is ongoing to better conceptualise and treat flares. This review highlights recent data on the definition and management of flares in axSpA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Many definitions of flares have been used in clinical trials, limiting the interpretation and comparison of studies. The expert group Assessment of SpondyloArthritis International Society (ASAS) developed a data-driven definition of flares\/disease worsening: an increase in Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) of at least 0.9 points, for use in axSpA clinical trials. Flares are more challenging to define in clinical practice because of their multifaceted nature. Qualitative studies have shown that flares from the patient's perspective are related not only to disease activity, but also to fatigue, mood, sleep and general well-being. The management of axSpA relies on a treat-to-target (T2T) strategy and aims at reaching clinical remission while monitoring closely disease activity to prevent and shorten flares.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The concept of flares has been clarified, and definitions have been developed for use in trials. The T2T approach aims at minimising flares in axSpA. The early recognition of flares and their severity may lead to better management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000883","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:00:14Z","timestamp":1655211614000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Defining and managing flares in axial spondyloarthritis"],"prefix":"10.1097","volume":"34","author":[{"given":"Krystel","family":"Aouad","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"},{"name":"Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"},{"name":"Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Rheumatology Department, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3899\/jrheum.090369","article-title":"Developing a standardized definition for disease \u2018flare\u2019 in rheumatoid arthritis (OMERACT 9 Special Interest Group)","volume":"36","author":"Bingham","year":"2009","journal-title":"J Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/annrheumdis-2016-209218","article-title":"Flare in axial spondyloarthritis. The dark side of the outcome","volume":"75","author":"Wendling","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/art.20350","article-title":"The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis","volume":"50","author":"Welsing","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R4-20250526","first-page":"209","article-title":"Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures","volume":"35","author":"Dougados","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/keab261","article-title":"Cut-off value to identify a flare using the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire: analysis of the TOSCA study","volume":"61","author":"Aouad","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250526","first-page":"keab711","article-title":"Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings","author":"Aouad","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jbspin.2014.12.008","article-title":"Flare in spondyloarthritis: thresholds of disease activity variations","volume":"82","author":"Godfrin-Valnet","year":"2015","journal-title":"Joint Bone Spine"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2015-208593","article-title":"Preliminary definitions of \u2018flare\u2019 in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-019-1873-3","article-title":"Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study","volume":"21","author":"Moreno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3\u200ayears of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with nonradiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.38014","article-title":"Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active nonradiographically evident axial spondyloarthritis who experience a flare","volume":"65","author":"Haibel","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1\u200ayear of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2\u200ayear data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5114\/reum.2017.69775","article-title":"Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy","volume":"55","author":"Sebastian","year":"2017","journal-title":"Reumatologia"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20250526","first-page":"884","article-title":"Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis","volume":"36","author":"Lian","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-017-3965-2","article-title":"Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2020-eular.1322","article-title":"Op0107 etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of re-embark, an open-label, phase IV trial","volume":"79","author":"den Bosch","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R23-20250526","first-page":"keab494","article-title":"BASDAI cut-off values corresponding to ASDAS cut-off values","author":"Chan Kwon","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/rheumatology\/kez480","article-title":"How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula","volume":"59","author":"Aranda-Valera","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"vi18","DOI":"10.1093\/rheumatology\/key176","article-title":"Defining the target: clinical aims in axial spondyloarthritis","volume":"57","author":"Marzo-Ortega","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"e001986","DOI":"10.1136\/rmdopen-2021-001986","article-title":"Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6\u200ayears","volume":"8","author":"Lucasson","year":"2022","journal-title":"RMD Open"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/rheumatology\/keaa692","article-title":"Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study","volume":"60","author":"Bengtsson","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00296-021-05055-3","article-title":"Disease activity outcome measures are only available in half of the electronic medical files of patients with axial spondyloarthritis followed in an outpatient clinic: the results of an audit of a tertiary-care rheumatology department","volume":"42","author":"Portier","year":"2021","journal-title":"Rheumatol Int"},{"key":"R29-20250526","first-page":"keab887","article-title":"Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis","author":"De Craemer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/rheumatology\/kep435","article-title":"Frequency and characteristics of disease flares in ankylosing spondylitis","volume":"49","author":"Cooksey","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/annrheumdis-2019-215458","article-title":"2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis","volume":"79","author":"Bech","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/annrheumdis-2015-208251","article-title":"Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort","volume":"75","author":"Desthieux","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R33-20250526","first-page":"954","article-title":"Definition of disease flare in ankylosing spondylitis: the patients\u2019 perspective","volume":"29","author":"Brophy","year":"2002","journal-title":"J Rheumatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"rkab082","DOI":"10.1093\/rap\/rkab082","article-title":"Understanding flare in axial spondyloarthritis: novel insights from daily self-reported flare experience","volume":"5","author":"Barnett","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3899\/jrheum.201317","article-title":"Evaluation and validation of a patient-completed psoriatic arthritis flare questionnaire","volume":"48","author":"Helliwell","year":"2021","journal-title":"J Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/art.39850","article-title":"Validation of FLARE-RA, a self-administered tool to detect recent or current rheumatoid arthritis flare","author":"Fautrel","year":"2017","journal-title":"Arthritis RheumatolV 69"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kev015","article-title":"Severe flare as a predictor of poor outcome in ankylosing spondylitis: a cohort study using questionnaire and routine data linkage","volume":"54","author":"Cooksey","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3899\/jrheum.160838","article-title":"Patient-reported flares in ankylosing spondylitis: a cross-sectional analysis of 234 patients","volume":"44","author":"Jacquemin","year":"2017","journal-title":"J Rheumatol"},{"key":"R39-20250526","first-page":"10547738221075784","article-title":"Patient goals for living with rheumatoid arthritis: a qualitative study","author":"Cozad","year":"2022","journal-title":"Clin Nurs Res"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/ken176","article-title":"Assessment of the impact of flares in ankylosing spondylitis disease activity using the flare illustration","volume":"47","author":"Stone","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s41927-019-0100-9","article-title":"Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort; characteristics, antecedents and sequelae","volume":"3","author":"McWilliams","year":"2019","journal-title":"BMC Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jbspin.2019.04.006","article-title":"Structural progression in axial spondyloarthritis","volume":"87","author":"Aouad","year":"2020","journal-title":"Joint Bone Spine"},{"key":"R43-20250526","first-page":"keab902","article-title":"Risk of flare after tapering or withdrawal of b-\/tsDMARDs in patients with RA or axSpA: A systematic review and meta-analysis","author":"Uhrenholt","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40744-021-00279-y","article-title":"Predictive Value of Active Sacroiliitis in MRI for Flare Among Chinese Patients with Axial Spondyloarthritis in Remission","volume":"8","author":"Zheng","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.rdc.2020.01.006","article-title":"Can imaging be a proxy for remission in axial spondyloarthritis?","volume":"46","author":"Aouad","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-eular.3148","article-title":"Sat0389 frequency of disease flares under long-term anti-tnf therapy in patients with early axial spondyloarthritis: results from the etanercept versus sulfasalazine in early axial spondyloarthritis trial","volume":"79","author":"Proft","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1093\/rheumatology\/keab049","article-title":"Association between environmental air pollution and rheumatoid arthritis flares","volume":"60","author":"Adami","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis,including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/acr.24788","article-title":"Motivators, barriers, and opportunity for E-health to encourage physical activity in axial spondyloarthritis: a qualitative descriptive study","volume":"74","author":"Passalent","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/rheumatology\/keaa480","article-title":"Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA)","volume":"60","author":"Molto","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:59Z","timestamp":1748294219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000883","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]}}}